Kylo Labs

Kylo Labs is an early-stage biotechnology company focused on transforming drug discovery through a proprietary functional genomics and proteomics platform. Headquartered in Cambridge, Massachusetts, the company was founded by leading scientists from the Broad Institute to map the complex interactions of the human proteome. By utilizing high-throughput screening and advanced computational tools, Kylo Labs identifies novel therapeutic targets that were previously considered undruggable. The company's technology aims to provide a deeper understanding of disease biology, particularly in oncology and immunology. Kylo Labs is backed by prominent venture capital firms, including F-Prime Capital and GV, to advance its mission of developing precision medicines.